# psoriasis - glm-5.2

- Benchmark system: raw
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4460
- Completion tokens: 4131
- Reasoning tokens: 
- Total tokens: 8591
- API requests reported: 
- Elapsed seconds: 257.597
- Final benchmark system: raw; file rank 4/5; original repeat 6; model vendor: Zhipu AI

---
Based on the provided transcriptomic data comparing psoriatic lesional skin to normal control skin, I have performed a multidimensional, evidence-grounded biological interpretation. The analysis strictly adheres to the statistical input provided and integrates established dermatological and immunological principles.

### 1. Overall Biological Interpretation

The transcriptomic profile of the psoriatic lesional skin reveals a profound dysregulation of epiderelial homeostasis, characterized by a massive shift toward hyperproliferation, aberrant differentiation, and acute inflammation. The data depict a disease state driven by a self-amplifying positive feedback loop: keratinocytes receive pro-inflammatory signals (notably IL-36, IL-20, and IL-26), which trigger a hyperproliferative response and a distorted differentiation program (evidenced by the upregulation of SPRR family members and keratins). 

In response to this stress and inflammatory signaling, the keratinocytes secrete potent antimicrobial peptides (e.g., defensins, S100 proteins) and alarmins, which in turn recruit and activate immune cells. This is corroborated by the upregulation of chemokines like CXCL13 and immune checkpoints like CD274 (PD-L1). Furthermore, the tissue exhibits significant metabolic reprogramming, favoring catabolic and inflammatory metabolic pathways (e.g., tryptophan degradation via KYNU) to sustain the high energetic and biosynthetic demands of the constantly renewing pathological epidermis. The presence of extracellular matrix remodeling signals and angiogenesis factors completes the picture of a highly dynamic, inflamed, and structurally altered tissue.

### 2. Core Biological Programs

**1. IL-36 / IL-20 Cytokine Signaling Network**
*   **Direction:** Upregulated
*   **Major supporting genes:** IL36A, IL36G, IL36RN, IL20, IL19, IL26
*   **Standardized Pathway:** KEGG: Cytokine-cytokine receptor interaction; Reactome: Cytokine Signaling in Immune System
*   **Explanation:** The concurrent, highly significant upregulation of IL-36 ligands (IL36A, IL36G), their antagonist (IL36RN), and downstream IL-20 family cytokines (IL20, IL19) strongly indicates a localized, auto-amplifying inflammatory circuit. IL-36 signaling in keratinocytes induces the production of IL-20 and IL-19, which drive epidermal acanthosis (thickening) and further chemokine production.
*   **Evidence and Limitations:** 
    *   *Evidence:* Direct expression evidence from the dataset; Disease-association evidence from established psoriasis literature.
    *   *Limitations:* Bulk RNA-seq cannot determine whether these cytokines are produced exclusively by keratinocytes or also by infiltrating immune cells. The upregulation of the antagonist IL36RN may represent a compensatory, yet insufficient, regulatory mechanism.

**2. Epidermal Barrier Remodeling and Cornified Envelope Assembly**
*   **Direction:** Upregulated
*   **Major supporting genes:** SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6
*   **Standardized Pathway:** GO: Epidermis development; Reactome: Keratinization
*   **Explanation:** The small proline-rich (SPRR) proteins, late cornified envelope (LCE) proteins, and specific keratins (KRT6A) are foundational components of the cornified envelope. Their massive upregulation, alongside gap junction proteins (GJB2, GJB6), marks an acceleration and distortion of the terminal differentiation program. In psoriasis, this reflects a reactive attempt to rebuild a compromised barrier under inflammatory stress.
*   **Evidence and Limitations:**
    *   *Evidence:* Direct expression evidence; well-documented tissue-specific expression patterns.
    *   *Limitations:* This program may represent a generic "wound healing" or "regenerative" response rather than a psoriasis-specific mechanism per se, as similar profiles appear in atopic dermatitis and contact dermatitis.

**3. Alarmins and Innate Antimicrobial Defense**
*   **Direction:** Upregulated
*   **Major supporting genes:** S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, DEFB103A, PI3
*   **Standardized Pathway:** GO: Innate immune response; Hallmark: Inflammatory Response
*   **Explanation:** S100 proteins (alarmins) and beta-defensins are signature antimicrobial peptides overexpressed in psoriatic skin. S100A8/A9 and S100A12 are potent activators of innate immunity via Toll-like receptor (TLR) and RAGE signaling. Their massive upregulation (e.g., S100A7A log2FC ~9.8) represents a primary bridge between keratinocyte stress and immune cell activation.
*   **Evidence and Limitations:**
    *   *Evidence:* Multiple independent highly significant genes in the dataset; robust literature support regarding their role in psoriasis pathophysiology.
    *   *Limitations:* While strongly associated with disease activity, it remains unclear from this data alone whether this program is a primary driver or an epiphenomenon secondary to barrier disruption.

**4. Tryptophan Catabolism and Metabolic Reprogramming**
*   **Direction:** Upregulated
*   **Major supporting genes:** KYNU, WNT5A, RRM2, CCNE1
*   **Standardized Pathway:** KEGG: Tryptophan metabolism; Hallmark: G2M Checkpoint
*   **Explanation:** KYNU (kynureninase) catalyzes the conversion of kynurenine, a key step in tryptophan catabolism. In psoriasis, increased tryptophan degradation serves dual purposes: providing local immunosuppression (via kynurenine action on T cells within the lesion) and generating NAD+ to meet the massive metabolic demands of hyperproliferative keratinocytes. This is coupled with cell-cycle programs (CCNE1, RRM2).
*   **Evidence and Limitations:**
    *   *Evidence:* Dataset expression levels; established biochemical pathway knowledge.
    *   *Limitations:* Single-gene reliance (KYNU) limits pathway-level confidence without metabolomic verification.

**5. Immune Checkpoint and Lymphocyte Recruitment**
*   **Direction:** Upregulated
*   **Major supporting genes:** CD274 (PD-L1), CXCL13, CXCR2, PRKCQ
*   **Standardized Pathway:** Reactome: Adaptive Immune System
*   **Explanation:** CD274 (PD-L1) upregulation indicates an immune suppressive/escape mechanism within the inflamed tissue, distinctively observed in psoriasis. Concurrently, CXCL13 (a B-cell and Tfh cell chemoattractant) and CXCR2 (neutrophil receptor) suggest specific immune cell recruitment. PRKCQ (PKC-θ) is a critical kinase in T-cell receptor signaling.
*   **Evidence and Limitations:**
    *   *Evidence:* Direct expression evidence; known immunological mechanism.
    *   *Limitations:* As this is bulk RNA-seq, attributing CD274 or PRKCQ expression solely to keratinocytes versus infiltrating immune cells is speculative without deconvolution.

### 3. Key Genes and Interaction Modules

1.  **IL36G**
    *   **Statistical Direction:** Upregulated (log2FC: 5.68, FDR: 1.43e-90)
    *   **Role:** driver of epidermal inflammation within the IL-36 program.
    *   **Interactions:** Regulatory interaction. It is expected to regulate the expression of IL20 and IL19 in keratinocytes; their co-expression in the dataset supports a pathway co-membership relationship.
2.  **S100A12**
    *   **Statistical Direction:** Upregulated (log2FC: 8.33, FDR: 7.94e-97)
    *   **Role:** central alarmin in the Antimicrobial Defense program.
    *   **Interactions:** Indirect or putative relationship with infiltrating immune cells via RAGE/TLR signaling, though direct physical binding targets are not present in the input data.
3.  **SPRR2A**
    *   **Statistical Direction:** Upregulated (log2FC: 7.31, FDR: 2.93e-85)
    *   **Role:** structural component in the Epidermal Barrier Remodeling program.
    *   **Interactions:** Direct physical interaction. SPRR proteins are crosslinked to involucrin and loricrin by transglutaminases to form the cornified envelope.
4.  **KYNU**
    *   **Statistical Direction:** Upregulated (log2FC: 4.42, FDR: 2.00e-91)
    *   **Role:** metabolic enzyme in the Tryptophan Catabolism program.
    *   **Interactions:** Enzymatic pathway co-membership with IDO1/TDO2 (not statistically prominent here), hence functionally linked rather than physically interacting.
5.  **CD274 (PD-L1)**
    *   **Statistical Direction:** Upregulated (log2FC: 3.44, FDR: 1.82e-63)
    *   **Role:** immune evasion/modulation marker.
    *   **Interactions:** Direct physical interaction. In tissue context, transmembrane PD-L1 physically binds PD-1 on activated T lymphocytes.
6.  **IL36A / IL36RN Module**
    *   **Statistical Direction:** Upregulated (IL36A log2FC: 11.37, FDR: 1.65e-98; IL36RN log2FC: 3.01, FDR: 3.85e-62)
    *   **Role:** represents an agonist/antagonist regulatory module.
    *   **Interactions:** Direct physical interaction. IL36RN is a binding protein that physically competes with IL36A for the IL-36 receptor, functioning as an intra-lesional checkpoint.
7.  **WNT5A**
    *   **Statistical Direction:** Upregulated (log2FC: 2.53, FDR: 1.04e-67)
    *   **Role:** non-canonical Wnt signaling driving dermal/epidermal crosstalk.
    *   **Interactions:** Regulatory interaction via Frizzled receptors (not listed) to drivecytoskeletal changes and keratinocyte migration.
8.  **KRT6A**
    *   **Statistical Direction:** Upregulated (log2FC: 4.30, FDR: 9.86e-68)
    *   **Role:** marker of hyperproliferative keratinocytes.
    *   **Interactions:** Direct physical interaction. Keratin 6A pairs with KRT6B/C and KRT16/17 to form intermediate filaments in stressed epidermis.
9.  **DEFB4A / DEFB4B Module**
    *   **Statistical Direction:** Upregulated (DEFB4A log2FC: 11.18, FDR: 2.18e-69)
    *   **Role:** host defense peptide amplifying local inflammation.
    *   **Interactions:** Pathway co-membership; functionally overlapping genes involved in antimicrobial response.
10. **PI3 (Peptidase Inhibitor 3)**
    *   **Statistical Direction:** Upregulated (log2FC: 9.24, FDR: 1.53e-69)
    *   **Role:** serine protease inhibitor regulating proteolytic activity in the cornified envelope.
    *   **Interactions:** Direct physical interaction. PI3 physically inhibits serine proteases (like KLKs) that otherwise degrade desmosomal proteins.

### 4. Validation Priorities

1.  **Mechanistic Hypothesis: The IL-36 Autocrine Loop**
    *   **Rationale:** To determine if IL-36 signaling is the primary trigger for the downstream IL-20/IL-19 expression.
    *   **Evidence:** Co-expression of IL36A/G, IL36RN, and IL20/IL19 in the dataset.
    *   **External Evidence:** Established literature confirms IL-36 signaling induces IL-20 in keratinocytes.
    *   **Next Step:** Use ex vivo lesional skin cultures treated with an IL-36 receptor antagonist to observe downregulation of IL20 and downstream hyperproliferative markers.
    *   **Status:** Supported hypothesis.

2.  **Therapeutic Target: Targeting the S100 Alarmin Axis**
    *   **Rationale:** S100A8/A9/A12 are highly upregulated and critically bridge innate and adaptive immunity.
    *   **Evidence:** S100A12 has an exceptionally high log2FC (8.33) and low FDR in this dataset.
    *   **External Evidence:** S100 proteins signal through RAGE and TLR4; while implicated in psoriasis, specific RAGE inhibitors have had mixed clinical success in other inflammatory diseases.
    *   **Next Step:** Evaluate the efficacy of RAGE/TLR4 blockade in a preclinical IMQ-induced psoriasis-like dermatitis model.
    *   **Status:** Exploratory hypothesis. (The existence of an inflammatory pathway does not guarantee success as a drug target).

3.  **Biomarker: Lung-Kidney Metabolic Axis in Skin**
    *   **Rationale:** Establishing kynurenine pathway gene expression as a severity biomarker.
    *   **Evidence:** Upregulation of KYNU suggests active metabolic reprogramming; tryptophan metabolites are detectable in serum.
    *   **Next Step:** Correlate skin RNA expression of KYNU with serum kynurenine/tryptophan ratios in a psoriasis patient cohort to test its utility as a non-invasive severity biomarker.
    *   **Status:** Exploratory hypothesis.

4.  **Interaction / Network Hypothesis: Epidermal Serine Protease / Antiprotease Balance**
    *   **Rationale:** To determine if the regulation of skin desquamation is driven by an imbalance in proteases and inhibitors.
    *   **Evidence:** Concurrent upregulation of PI3 and SERPINB family members, alongside aberrant differentiation markers (SPRRs).
    *   **External Evidence:** Overexpression of SERPINB4 and PI3 in psoriasis is known to counteract the hyper-proteolytic environment.
    *   **Next Step:** Perform proteomic quantification (e.g., targeted mass spectrometry) of serine protease activity in lesional vs. non-lesional stratum corneum extracts.
    *   **Status:** Supported hypothesis.

5.  **Confounding or Composition Check: Immune Cell Deconvolution**
    *   **Rationale:** To ensure that the identified "Immune Checkpoint/Lymphocyte" program is not simply an artifact of variable immune cell infiltration between samples.
    *   **Evidence:** Signals like CXCL13 and CD274 may derive from a minority of cells embedded within the bulk keratinocyte matrix.
    *   **External Evidence:** Established that CXCL13+ Tfh cells and PD-L1+ cells infiltrate psoriasis plaques.
    *   **Next Step:** Apply computational deconvolution algorithms (e.g., CIBERSORTx) to the dataset, or perform single-cell RNA sequencing on the same tissue.
    *   **Status:** Supported hypothesis (necessary control).

### 5. Evidence Grounding

The above interpretations draw upon distinct types of evidence:

*   **Direct evidence from the input dataset:** The FDR and log2FC values provide the statistical foundation for gene prioritization. High log2FC values (e.g., IL36A, S100A12, DEFB4A) reinforce absolute biological magnitude.
*   **Pathway / ontology evidence:** Genes were grouped into functional modules (e.g., IL-20 family cytokines, SPRRs) based on historical and standardized pathway databases.
*   **Protein interaction evidence:** The assertion that IL36RN is an IL-36 receptor antagonist or that PI3 inhibits serine proteases relies on established direct physical interaction evidence (e.g., receptor binding assays, crystal structures), not merely co-expression.
*   **Expression or tissue-specific evidence:** Terms like "keratinization" and "epidermal development" firmly contextualize the transcriptomic signals to the tissue source (skin).
*   **Disease-association evidence:** Concurrent literature shows that specific pathways (IL-23/IL-17/IL-36 axis) are actively targeted by successful psoriasis biologics, aligning with the detected signals.
*   **Genetic or clinical evidence:** The upregulation of CD274 (PD-L1) corresponds to known efficacy of checkpoint modulators in radically altering skin inflammation.

*Note on Redundancy:* Some pathway evidence (e.g., "Antimicrobial Defense") and disease-association evidence may overlap, as alarmins are both biological pathway components and specific disease biomarkers in psoriasis.

### 6. Limitations and Alternative Explanations

1.  **Tissue or Cell-composition Differences:** Bulk RNA-seq provides an averaged signal. Highly upregulated immune genes (CXCL13, CD274) may represent an increase in the proportion of infiltrating immune cells rather than upregulation in resident keratinocytes. *Investigation:* Single-cell RNA sequencing or multiplex immunofluorescence is required to map these signals to specific cell types.
2.  **Disease Severity:** The dataset lacks clinical metadata for disease severity (e.g., PASI score). The transcriptomic profile likely represents moderate-to-severe plaque psoriasis, as mild disease may not exhibit such pronounced KYNU or IL36 upregulation. *Investigation:* Stratify expression by clinical severity scores in future cohorts.
3.  **Treatment Exposure:** It is unknown whether lesional skin was harvested from patients on current systemic treatments (e.g., biologics, methotrexate). Such treatments drastically alter transcriptomic landscapes. *Investigation:* Mandate washout periods before biopsy in prospective studies.
4.  **Broad or Nonspecific Pathway Enrichment:** Programs like "Epidermal Barrier Remodeling" reflect general wound-healing and hyperproliferation. Similar expression patterns are seen in healing skin or eczematous skin; these signals are not uniquely causal to psoriasis. *Investigation:* Contrast the specific fold-changes and distinct gene clusters (e.g., IL36 + SPRR combination) against other dermatoses to establish psoriasis-specific signatures.
5.  **Association-versus-Causation Ambiguity:** While the IL-36 axis is strongly implicated, the data only show correlation in expression. Whether IL36G directly causes the SERPINB/SPRR upregulation cannot be proven without targeted perturbation experiments. *Investigation:* Employ ex vivo lesional explant cultures and neutralizing antibodies to test具体的 causality.
